Business Wire

CSC and Palo Alto Networks Join Forces to Fortify Domain Security for Cortex XSOAR, XSIAM, and XPANSE Users and CSC Domain Registrar Clients

23.7.2024 16:00:00 EEST | Business Wire | Press release

Share

CSC, an enterprise-class domain registrar and world leader in mitigating domain security, domain name system (DNS), and digital brand threats, today announces a technical collaboration with Palo Alto Networks to boost domain security for users of Palo Alto Network’s Cortex XSOAR, XSIAM, and XPANSE solutions and for CSC's domain registrar clients. Under this collaboration, CSC will use domain name, DNS, and secure sockets layer (SSL) portfolio data—in conjunction with intelligence and capabilities within Cortex—to contextualize risks and facilitate the remediation of threats.

This new integration pack for our CSCDomainManager℠ application programming interface (API) is now available for download via the Cortex marketplace. As part of the relationship, joint Cortex and CSC clients can also benefit from a complimentary, defined package of domain name and URL phishing takedowns that target corporate domain name portfolios. This will help secure clients against threat vectors targeting their brands online—working to fortify their overall security posture.

“Given the increasing threats faced by organizations and their consumers due to brand impersonation and other DNS security issues, we're excited to extend CSC's robust data sets and solutions to our clients conveniently through their existing Cortex products. Going after malicious actors at their root via takedowns and ensuring proper DNS security to prevent hijacking and other risks are powerful proactive steps to prevent damaging security incidents,” says Andrew Scott, director of product at Palo Alto Networks.

“CSC detects domain threats, online brand and DNS abuse, and fraud to protect companies from cyberattacks caused by compromised or fraudulent domains,” says Mark Calandra, president of CSC's Digital Brand Services division. “Our inclusion in the Cortex marketplace is a testament to our capabilities and in-depth knowledge of the domain security landscape and boosts the visibility of our services by seamlessly integrating into the workflow of users focused on optimizing their cybersecurity posture.”

“In today’s ever-evolving cybersecurity landscape, integrating robust domain security and brand protection measures is not just a necessity, but a strategic imperative. Our collaboration with Palo Alto Networks exemplifies our commitment to delivering a comprehensive security posture that address the blended threats our clients face,” says Ihab Shraim, chief technology officer at CSC’s Digital Brand Services. “By leveraging advanced intelligence and capabilities, we empower businesses to proactively defend against domain-related cyber threats and ensure the integrity of their digital brand presence.”

Key benefits of the CSC and Cortex integration include:

  • Cortex XSOAR: Automates threat detection and incident response, simplifying management of domain-related security.
  • Cortex XSIAM: Analyzes data to identify vulnerabilities and enhances proactive threat mitigation strategies.
  • Cortex XPANSE: Provides visibility into and secures internet-facing assets, improving detection of vulnerable domains.
  • CSC Enhanced Domain Registrar Security: Strengthens defenses against hijacking, phishing and cyber threats. Implements continuous monitoring to protect against evolving domain security threats.

This partnership underscores the commitment of both CSC and Palo Alto Networks to deliver state-of-the-art security solutions, ensuring the safety and integrity of digital assets for their clients.

About CSC
CSC is the trusted security and threat intelligence provider of choice for the Forbes Global 2000 and the 100 Best Global Brands (Interbrand®) with focus areas in domain security and management, along with digital brand and fraud protection. As global companies make significant investments in their security posture, our DomainSec℠ platform can help them understand cybersecurity oversights that exist and help them secure their online digital assets and brands. By leveraging CSC’s proprietary technology, companies can solidify their security posture to protect against cyber threat vectors targeting their online assets and brand reputation, helping them avoid devastating revenue loss. CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—with a multidimensional view of various threats outside the firewall targeting specific domains. Fraud protection services that combat phishing in the early stages of attack round out our solutions. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com.

About Palo Alto Networks
Palo Alto Networks is the world's cybersecurity leader. We innovate to outpace cyberthreats, so organizations can embrace technology with confidence. We provide next-gen cybersecurity to thousands of customers globally, across all sectors. Our best-in-class cybersecurity platforms and services are backed by industry-leading threat intelligence and strengthened by state-of-the-art automation. Whether deploying our products to enable the Zero Trust Enterprise, responding to a security incident, or partnering to deliver better security outcomes through a world-class partner ecosystem, we're committed to helping ensure each day is safer than the one before. It's what makes us the cybersecurity partner of choice.

At Palo Alto Networks, we're committed to bringing together the very best people in service of our mission, so we're also proud to be the cybersecurity workplace of choice, recognized among Newsweek's Most Loved Workplaces (2023, 2022, 2021), with a score of 100 on the Disability Equality Index (2023, 2022), and HRC Best Places for LGBTQ+ Equality (2022). For more information, visit www.paloaltonetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240723899433/en/

Contacts

Joyson Cherian
W2 Communications
CSC@w2comm.com
CSC® News Room -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.cscglobal.
com%2Fservice%2Fcsc%2Fpress%2F&esheet=54097829&newsitemid=20240723899433&lan=en-
US&anchor=CSC%26%23174%3B+News+Room&index=5&md5=172e8f1da9eacf4897deb50f6768ca5d

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release

SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.

Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release

Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye